Entyvio Prices, Coupons, Copay Cards & Patient Assistance
Entyvio (vedolizumab) is a member of the selective immunosuppressants drug class and is commonly used for Crohn's Disease, Crohn's Disease - Maintenance, and Ulcerative Colitis.
Entyvio prices
Intravenous Powder For Injection
300 mg Entyvio intravenous powder for injection from $9,150.66 for 1 powder for injection
| Quantity | Per unit | Price |
|---|---|---|
| 1 | $9,150.66 | $9,150.66 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Get your FREE Drugs.com Discount Card
Save up to 80% off the cost of prescription drugs and OTC medicines valid at over 65,000 pharmacies.
This is a drug discount program, not an insurance plan.
Entyvio Coupons, Copay Cards and Rebates
Entyvio offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Entyvio Connect Co-Pay Program
Eligible commercially insured patients may pay as little $5 per dose every 8 weeks.
- Applies to:
- Entyvio
- Number of uses:
- every 8 weeks
Form more information phone: 844-368-9846 or Visit website
Entyvio Start Program
Patients who are NEW to the medication and have received a denied prior authorization from a commercial health plan may be eligible to receive their medication for FREE for up to 1 year.
- Applies to:
- Entyvio
- Number of uses:
- for up to 1 year
Form more information phone: 844-368-9846 or Visit website
Entyvio Connect Bridge Program
Eligible commercially insured patients with a temporary loss or gap in insurance coverage may be provided with medication at no cost for up to 6 months.
- Applies to:
- Entyvio
- Number of uses:
- up to 6 months
Form more information phone: 844-368-9846 or Visit website
Patient Assistance & Copay Programs for Entyvio
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Entyvio (vedolizumab) Injection; IV
- Entyvio Pen (vedolizumab) Injection; Subcutaneous
More information please phone: 866-316-7263 Visit website
Provider: Entyvio Patient Assistance Program
Eligibility requirements:- Contact program for details.
- At or below 500% of FPL
- Not applicable
- Must be residing in the US or US territory
- Entyvio (vedolizumab) Injection; IV
- Entyvio Pen (vedolizumab) Injection; Subcutaneous
More information please phone: 855-368-9846 Visit website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
See also:
More about Entyvio (vedolizumab)
- Check interactions
- Compare alternatives
- Reviews (167)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
- En español